Michael Jay, a professor of pharmaceutical sciences at the University of Kentucky College of Pharmacy, has received a large federal grant to protect the U.S. population from the consequences of nuclear terrorism. His mission is to develop an orally administered treatment to be used in radiation emergencies, such as exposure to the effects of radiological dispersion devices. (University of Kentucky News)